Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  The Lancet

• Publication date

  1985-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(85)90176-XPMID 2861523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-lipopolysaccharide immunotherapy for gram-negative septicaemia.

  1984cited by this paper
• Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.

  1984cited by this paper
• Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.

  1983cited by this paper
• Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

  1982cited by this paper
• Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

  1982cited by this paper
• Infection surveillance and control in the severely traumatized patient.

  1981cited by this paper
• Patterns of mortality in a surgical intensive care unit.

  1981cited by this paper
• Nosocomial bacteremia. An epidemiologic overview.

  1981cited by this paper
• The surgical intensive care unit: current concepts in infection.

  1980cited by this paper
• Neutralization of meningococcal endotoxin by antibody to core glycolipid

  1978cited by this paper
• Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis.

  1976cited by this paper
• The injury severity score: an update.

  1976cited by this paper
• Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

  1975cited by this paper
• Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

  1975cited by this paper
• Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.

  1973cited by this paper
• Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

  1973cited by this paper
• Treatment and prevention of intravascular coagulation with antiserum to endotoxin.

  1973cited by this paper
• Passive immunization against the local Shwartzman reaction.

  1972cited by this paper
• Type-specific and cross-reactive antibodies in gram-negative bacteremia.

  1972cited by this paper
• Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli.

  1972cited by this paper
• The surgical intensive care unit.

  1969cited by this paper
• BMD : biomedical computer programs

  1967cited by this paper
• PROTECTION AGAINST LETHALITY OF E. COLI ENDOTOXIN WITH “O” ANTISERUM *

  1966cited by this paper
• THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT.

  1965cited by this paper

• Endothelial GSDMD underlies LPS-induced systemic vascular injury and lethality

  2025cites this paper
• Hit ‘em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target

  2023cites this paper
• A potential new pathway for heparin treatment of sepsis-induced lung injury: inhibition of pulmonary endothelial cell pyroptosis by blocking hMGB1-LPS-induced caspase-11 activation

  2022cites this paper
• A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis

  2021cites this paper
• The study of usefulness of low-dose IgG for patients with septic disseminated intravascular coagulation.

  2020cites this paper
• The current state of immunization against Gram-negative bacteria in children: a review of the literature

  2020cites this paper
• Chapter 22 – Meta-analysis of Clinical Trials

  2018cites this paper
• Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4.

  2017cites this paper
• Part 2: Biologic Effects and Clinical Evaluationsof Anti endotoxin Therapies

  2017cites this paper
• Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae

  2017cites this paper
• Sepsis: Staging and Potential Future Therapies

  2017cites this paper
• Caspase-11–mediated endothelial pyroptosis underlies endotoxemia-induced lung injury

  2017cites this paper
• IMMUNOGENICITY OF ESCHERICHIA COLI ROUGH MUTANT BACTERIN IN CHICKENS

  2016cites this paper
• IMMUNOGENICITY OF ESCHERICHIA COLI ROUGH MUTANT

  2016cites this paper
• Toll-Like Receptors

  2016cites this paper
• Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

  2015cites this paper
• Back to the future

  2014cites this paper
• Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum.

  2014cites this paper
• Treatment of Endotoxemia

  2014cites this paper
• Anti-endotoxin vaccines

  2013cites this paper
• Endotoxemia: correlation with gram-negative bacteremia and association with outcome

  2013cites this paper
• Towards Clinical Applications of Anti-endotoxin Antibodies; A Re-appraisal of the Disconnect

  2013cites this paper
• The quest for the magic bullet: Centoxin, Drotrecogin Alfa and lessons not learned

  2013cites this paper
• Antiendotoxin Monoclonal Antibodies in Sepsis

  2012cites this paper
• Innovative Therapies for Sepsis

  2012cites this paper
• Meta-analysis of Clinical Trials

  2012cites this paper
• Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection

  2011cites this paper
• Использование поликлональных иммуноглобулинов в лечении сепсиса

  2011cites this paper
• Targeting endotoxin in the treatment of sepsis.

  2010cites this paper
• Development of an anti-endotoxin vaccine for sepsis.

  2010cites this paper
• Protein to Regulate Endotoxin Function Protein CRISPLD 2 Is a Critical Serum The Novel Lipopolysaccharide-Binding and

  2009cites this paper
• The Novel Lipopolysaccharide-Binding Protein CRISPLD2 Is a Critical Serum Protein to Regulate Endotoxin Function1

  2009cites this paper
• Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting?

  2009cites this paper
• Anti-lipopolysaccharide antibodies measured by enzyme-immunoassay in Danish blood donors.

  2009cites this paper
• Study of the range of antibody levels and activities of acinetobacter calcoaceticus-acinetobacter baumannii complex and haemophilus influenzae lipopolysaccharides.

  2009cites this paper
• Once is not enough: clinical trials in sepsis

  2008cites this paper
• A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R 5 9 5 I i pop 0 I ysacc h a r ide

  2008cites this paper
• Targeting the lipopolysaccharides: still a matter of debate?

  2008cites this paper
• Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1*

  2007cites this paper
• Using Secondary Data in Statistical Analysis

  2007cites this paper
• Histopathologische Veränderungen am Skelettmuskel nach chronischer Inflammation mit Corynebacterium parvum mit und ohne Immobilisation-Experimentelle Untersuchungen an der Ratte

  2007cites this paper
• Intravenous polyclonal IgM‐enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis

  2006cites this paper
• laboratory and animal investigations Pseudomonas aeruginosa Compared with Escherichia coil Produces Less Endotoxemia but More Cardiovascular Dysfunction and Mortality in a Canine Model of Septic Shock *

  2006cites this paper
• Correlation of Protein and Gene Expression Profiles of Inflammatory Proteins After Endotoxin Challenge in Human Subjects

  2005cites this paper
• Iii 111 ! ! 1 ! 1 iiiiiiii iiiliii ? iii : iiiiii iii iiiii : : iiii ! ii ! iiiiliiiii i iii !

  2005cites this paper
• Interférences avec la cascade immuno-inflammatoire

  2005cites this paper
• New aspects in the treatment of gram-negative bacteraemia and septic shock

  2005cites this paper
• Adjunctive therapy in sepsis : a critical analysis of the clinical trial programme

  2005cites this paper
• Immunological perspectives in prevention and treatment of nosocomial pneumonia

  2005cites this paper
• Anti‐inflammatory and antimicrobial effect of lectin from Lonchocarpus sericeus seeds in an experimental rat model of infectious peritonitis

  2005cites this paper
• Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.

  2004cites this paper
• Report on the European Conference on Septic Shock of the European Society of Intensive Care Medicine and the European Shock Society, Brussels, Belgium, March 1–2, 1987

  2004cites this paper
• Molecular basis of endothelial dysfunction in sepsis.

  2003cites this paper
• Update on Anti-Endotoxin Therapies

  2003cites this paper
• Passive immunization as prophylaxis: when and where will this work?

  2003cites this paper
• Pathogenèse et traitement de la septicémie

  2003cites this paper
• Disease-reducing potential of increased immunity to shared lipopolysaccharide core antigens of Gram-negative bacteria by immunizing swine with Escherichia coli J 5

  2003cites this paper
• Such stuff as dreams are made on: mediator-directed therapy in sepsis

  2003cites this paper
• Therapeutic approaches to innate immunity: severe sepsis and septic shock

  2003cites this paper
• Pathogenese und Therapie der Sepsis

  2003cites this paper
• Factors predisposing to bacterial invasion and infection.

  2002cites this paper
• Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

  2002cites this paper
• Chapter 16 – Using Secondary Data in Statistical Analysis

  2002cites this paper
• The Immunology of Sepsis

  2002cites this paper
• Immunotherapy in the management of sepsis.

  2002cites this paper
• Biological response modifiers and infectious diseases: Actual and potential therapeutic agents

  2002cites this paper
• Toll-like receptors.

  2002cites this paper
• Immunotherapy of Bacterial Infections and Sepsis

  2002cites this paper
• Novel therapies for sepsis: antiendotoxin therapies

  2002cites this paper
• Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.

  2001cites this paper
• Septic shock.

  2001cites this paper
• Outer membrane protein A (OmpA), peptidoglycan-associated lipoprotein (PAL), and murein lipoprotein (MLP) are released in experimental Gram-negative sepsis

  2001cites this paper
• 11. IMMUNOMODULATION IN SEPSIS

  2001cites this paper
• Inhibitory effect of DCDC on lipopolysaccharide-induced nitric oxide synthesis in RAW 264.7 cells.

  2001cites this paper
• Immunomodulation in Sepsis

  2001cites this paper
• Bactericidal/Permeability-Increasing Protein Attenuates Systemic Inflammation and Acute Lung Injury in Porcine Lower Limb Ischemia–Reperfusion Injury

  2001cites this paper
• Is There a Place in the Treatment for Hyperimmune Globulins of Refractory Infections

  2001cites this paper
• Is there a place for hyperimmune globulins in the treatment of refractory infections?

  2001cites this paper
• Endotoxin and adjunctive therapies in gram-negative sepsis

  2001cites this paper
• New therapies and vaccines for meningococcal disease

  2001cites this paper
• Passive immunity in prevention and treatment of infectious diseases.

  2000cites this paper
• Immunotherapy and Vaccines

  2000cites this paper
• Endotoxin immunization

  2000cites this paper
• Outer Membrane Protein A, Peptidoglycan-Associated Lipoprotein, and Murein Lipoprotein Are Released by Escherichia coli Bacteria into Serum

  2000cites this paper
• The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides

  2000cites this paper
• Anti-inflammatory therapies in sepsis and septic shock

  2000cites this paper
• Release of gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5.

  2000cites this paper
• Protective features of monoclonal antibodies to Escherichia coli during experimental infection of mice with homologous and heterologous serotypes of E. coli.

  2000cites this paper
• Passive Immunity in Prevention and Treatment of Infectious Diseases

  2000cites this paper
• Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia.

  1999cites this paper
• Anti-Endotoxin Antibodies in Sepsis: A Critical Evaluation

  1999cites this paper
• Lipopolyamines: Novel Antiendotoxin Compounds That Reduce Mortality in Experimental Sepsis Caused by Gram-Negative Bacteria

  1999cites this paper
• Immunotherapy of sepsis: flawed concept or faulty implementation?

  1999cites this paper
• Síndrome da resposta inflamatória sistêmica/sepse 3/4 revisão e estudo da terminologia e fisiopatologia

  1999cites this paper
• Shock: A comparative physiologic approach to mechanisms and therapy

  1999cites this paper
• Gram-negative bacterial sepsis and the sepsis syndrome.

  1999cites this paper
• Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme.

  1999cites this paper
• Study of the protective effects of hyperimmune immunoglobulins G and M against endotoxin in mice and rats

  1999cites this paper
• Los anticuerpos monoclonales en el tratamiento de la sepsis provocada por microorganismos gramnegativos

  1998cites this paper
• The effect of of glucocorticoids on grain dust-induced airway disease.

  1998cites this paper